Development of a functional outcome measure for riboflavin transporter deficiency

被引:1
|
作者
Fennessy, Jack R. [1 ]
Donlevy, Gabrielle A. [1 ,2 ]
Mckay, Marnee J. [1 ]
Burns, Joshua [1 ,2 ]
Cornett, Kayla M. D. [1 ,2 ]
Menezes, Manoj P. [3 ,4 ,5 ]
机构
[1] Univ Sydney, Fac Med & Hlth, Sch Hlth Sci, Sydney, NSW, Australia
[2] Sydney Childrens Hosp Network, Paediat Gait Anal Serv New South Wales, Westmead, NSW, Australia
[3] Univ Sydney, Westmead Clin Sch, Fac Med & Hlth, Childrens Hosp, Sydney, NSW, Australia
[4] Childrens Hosp Westmead, TY Nelson Dept Neurol & Neurosurg, Sydney, NSW, Australia
[5] Childrens Hosp Westmead, TY Nelson Dept Neurol & Neurosurg, Westmead, NSW 2145, Australia
关键词
clinical outcome assessment; clinical trials; endpoint; performance outcome measure; riboflavin transporter deficiency; MARIE-TOOTH DISEASE; REFERENCE VALUES; MUTATIONS; VARIABILITY; VALIDATION; SCALE;
D O I
10.1111/jns.12619
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and AimsRiboflavin transporter deficiency (RTD) is a progressive inherited neuropathy of childhood onset, characterised clinically by pontobulbar palsy, sensory ataxia, sensorineural deafness, muscle weakness, optic atrophy and respiratory failure. A robust and responsive functional outcome measure is essential for future clinical trials of disease-modifying therapies including genetic therapies. The Charcot-Marie-Tooth disease Pediatric Scale (CMTPedS) is a well-validated outcome measure for CMT and related neuropathies, and might have utility for measuring disease progression in individuals with RTD. However, the CMTPedS requires modifications to account for phenotypic differences between children with CMT and RTD. The aim of this study was to develop a functional outcome measure based on the CMTPedS for specific use in individuals with RTD.MethodsThe CMTPedS data collected over the last 10 years in individuals with RTD attending the Peripheral Neuropathy Management Clinic at the Children's Hospital at Westmead (Sydney, Australia) were reviewed to evaluate each item within the CMTPedS. A literature review of articles published until September 2021 for functional outcome measures generated an item pool for pilot testing. The results of this pilot testing, alongside analysis of existing CMTPedS item scores in the RTD cohort, informed the modification of the CMTPedS.ResultsCMTPedS data were reviewed for eight individuals over the past 10 years. Two items were identified as requiring modification or removal and additional items of proximal strength and function needed to be considered. Six studies were identified in the literature review, and five items were selected for pilot testing. 'Shoulder internal rotation' and the '30-s sit to stand test' were added as proximal measures of strength and function. The composite balance item comprising nine tasks in the CMTPedS showed a ceiling effect and was replaced with the single 'Feet apart on a line eyes open' balance item. 'Pinprick sensation' was removed due to a floor effect.InterpretationThis study provides preliminary evidence that the Riboflavin Transporter Deficiency Pediatric Scale (RTDPedS) is a functional outcome measure covering strength, upper and lower limb function, balance and mobility for individuals with RTD to assess disease severity and progression in clinical trials and cohort studies.
引用
收藏
页码:185 / 192
页数:8
相关论文
共 50 条
  • [31] SUBCLINICAL RIBOFLAVIN DEFICIENCY IS ASSOCIATED WITH OUTCOME OF SERIOUSLY ILL PATIENTS
    SHENKIN, SD
    CRUICKSHANK, AM
    SHENKIN, A
    CLINICAL NUTRITION, 1989, 8 (05) : 269 - 271
  • [32] Asymmetry in Quadriceps Rate of Force Development as a Functional Outcome Measure in TKA
    Maffiuletti, Nicola A.
    Bizzini, Mario
    Widler, Katharina
    Munzinger, Urs
    CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2010, 468 (01) : 191 - 198
  • [33] Development of a multiple sclerosis functional composite as a clinical trial outcome measure
    Cutter, GR
    Baier, ML
    Rudick, RA
    Cookfair, DL
    Fischer, JS
    Petkau, J
    Syndulko, K
    Weinshenker, BG
    Antel, JP
    Confavreux, C
    Ellison, GW
    Lublin, F
    Miller, AE
    Rao, SM
    Reingold, S
    Thompson, A
    Willoughby, E
    BRAIN, 1999, 122 : 871 - 882
  • [34] Review of Riboflavin Transporter Deficiency Syndrome: Sameness in Genotype occurs with Variations in Phenotype
    Ukpong, Christopher
    Einstein, George
    Tulp, Orien
    FASEB JOURNAL, 2020, 34
  • [35] Long-term outcomes in children with riboflavin transporter deficiency and surveillance recommendations
    Fennessy, Jack R.
    Cornett, Kayla M. D.
    Donlevy, Gabrielle A.
    Mckay, Marnee J.
    Burns, Joshua
    Menezes, Manoj P.
    DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2025, 67 (03): : 405 - 415
  • [36] ACUTE RIBOFLAVIN DEFICIENCY AND MAMMARY TUMOR DEVELOPMENT IN MICE
    KALTER, H
    ANATOMICAL RECORD, 1962, 142 (02): : 311 - &
  • [37] Riboflavin deficiency
    Fox, IS
    BRITISH MEDICAL JOURNAL, 1942, 1942 : 678 - 679
  • [38] DEVELOPMENT OF RIBOFLAVIN DEFICIENCY IN ALCOHOL-FED HAMSTERS
    KIM, CI
    ROE, DA
    DRUG-NUTRIENT INTERACTIONS, 1985, 3 (02) : 99 - 107
  • [39] Development and Validation of a Functional Outcome Measure in the National Health and Aging Trends Study
    Gill, Thomas M.
    Williams, Christianna S.
    JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2018, 73 (08): : 1111 - 1118
  • [40] Development and Validation of a Movement and Activity in Physical Space Score as a Functional Outcome Measure
    Herrmann, Stephen D.
    Snook, Erin M.
    Kang, Minsoo
    Scott, CaraLynn B.
    Mack, Mick G.
    Dompier, Thomas P.
    Ragan, Brian G.
    ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION, 2011, 92 (10): : 1652 - 1658